Heme/Onc Flashcards
Drug class for iron
Hematinic
MoA for iron
supplement
Indications of iron
iron deficiency
SE/ADRs for iron
N/V/D
constipation, abd cramps
black stools
anaphylaxis
Contra-indications for iron
hemochromatosis, anaphylaxis, hemolytic anemia
Dx-Dx for iron
antacids, phenytoin
quinolone & tetracycline abxs bind Fe
monitoring for iron
serum ferritin
transferrin saturation
Hgb
reticulocytes
Drug class for deferoxamine
iron chelator
indications for deferoxamine
excessive serum iron levels
MoA for deferoxamine
chelates iron from hemosiderin, ferritin, transferrin (not from hemoglobin or cytochromes)
SE/ADRs for deferoxamine
fever, leg cramps tachy, hypotension allergic drug runs 'pulmonary syndrome' neurotoxicity
Drug class for Cyanacobalamin B12
vitamin
MoA for cyanacobalamin B12
rate limiting cofactor in conversion of folate to active form & DNA synthesis
indications for cyanacobalamin B12
B12 deficiency (megaloblastic anemia, peripheral neuropathy, depression, CVD)
SE/ADRs for cyanacobalamin B12
painful by injection site
Dx-Dx for cyanacobalamin B12
long term acid suppression therapy
metformin (can inhibit B12 absorption), phenytoin
monitoring for cyanacobalamin B12
[B12, folate] serum
MMA levels, homocysteine levels
Drug class for folic acid
nutritional
MoA for folic acid
cofactor in DNA synthesis
indications fo folic acid
folate deficiency (megaloblastic anemia, prevention of neural tube defects, CVD)
SE/ADRs for folic acid
bronchospasms, flushing, pruritis (rare)
Contra-indications for folic acid
hypersensitivity
Dx-Dx for folic acid
- phenobarbitol, phenytoin, primidone levels decreased by folic acid
- phenytoin, trimethoprim, methotrexate deplete folic acid levels
monitoring for folic acid
serum folic acid
RBC folate level
Drug class for epoetin alfa
erythrocyte-stimulating agent
MoA for epoetin alfa
stimulates erythroid proliferation & differentiation; induces release of reticulocytes
indications for epoetin alfa
low RBC secondary to ESRD, HIV, antineoplastic therapy, RA
SE/ADRs for epoetin alfa
secondary impact on iron deficiency, clotting
hypertensions, thrombosis, seizures
What disease should we think about using Epoetin alfa (Epogin) for?
Chronic kidney disease
Drug class for filgrastim
myeloid growth factor: G-CSF
MoA for filgrastim
- stimulates proliferation & differentiation of myeloid cells
- increase phagocytic capacity & prolongs survival of mature neutrophils
- mobilizes peripheral neutrophils
indications for filgrastim
neutropenia secondary to chemotherapy
SE/ADRs for filgrastim
fever, petechiae, bone pain
splenomegaly
What is the major cause for people stopping iron supplementation?
GI complications
Which form has the most elemental iron in it?
FeSO4
Why don’t you want to give Epogin with Hgb levels over 11?
increased risk for blood clots, MI, and strokes
How long does it take to completely correct & replete iron stores? But when will you see effects of iron supplementation?
3-6 months for complete restoration
see increase in 2-3 weeks
Drug class for unfractionated heparin
indirect thrombin inhibitors
MoA for unfractionated heparin
accelerates degradation of XA & thrombin (Ila)
indications for unfractionated heparin
thrombotic disorders
SE/ADRs for unfractionated heparin
bleeding, allergic rxn, alopecia
long term: osteoporosis; HIT (after 7 days); skin necrosis
Contra-indications for unfractionated heparin
prior HIT, pre-existing severe thrombocytopenia, intra-cranial bleeding
Dx-Dx for unfractionated heparin
other anticoagulants
tNSAIDs
NTG decreases effectiveness
monitoring for unfractionated heparin
aPTT, platelet counts
H&H
fecal occult blood
Why can’t unfractionated heparin lyse an established clot?
it has no fibrinolytic activity
Drug class for low-molecular-weight heparin (lmwh enoxaparin)
indirect thrombin inhibitors
MoA for low-molecular-weight heparin
increases degradation of Xa
indications for low-molecular-weight heparin
acute coronary syndrome, DVT (prevention & treatment)
SE/ADRs for low-molecular-weight heparin
- injection site hematoma, fever, increased AST/ALT
- bleeding
- hypersensitivity rxn
Contra-indications for low-molecular-weight heparin
- active major bleeding
- hypersensitivity to pork, heparin
- thrombocytopenia
monitoring for low-molecular-weight heparin
platelet count, CrCl
How is low-molecular-weight heparin eliminated?
renally
Drug class for fondaparinux
indirect thrombin inhibitors
MoA for fondaparinux
accelerates factor Xa degradation
Indications for fondaparinux
- DVT prophylaxis
- TX acute PE/DVT without PE
SE/ADRs for fondaparinux
- moderate thrombocytopenia
- bleeding, rash
- fever, nausea
- anemia, edema
Contra-indications for fondaparinux
- hypersensitivity
- active bleeding
- CrCl less than 30ml/min
Dx-Dx for fondaparinux
-tNSAIDs
o/w minimal
monitoring for fondaparinux
CBC, CrCl
fecal occult blood
How is fondaparinux administered?
only sub-Q
Drug class for protamine sulfate
antagonist of indirect thrombin inhibitors
MoA for protamine sulfate
binds to heparin & neutralizes its anticoagulant effect
indications for protamine sulfate
excess heparin impact
Drug class for dabigatran
oral direct thrombin inhibitor
MoA for dabigatran
directly inhibits thrombin (Ila) action to convert fibrinogen to fibrin; inhibits platelet aggregation
indications for dabigatran
prevent stroke in non-valvular A fib
SE/ADRs for dabigatran
bleeding, gastric irritation
gastritis
Contra-indications for dabigatran
severe renal disease (CrCl less than 15 ml/min)
Dx-Dx for dabigatran
P-gp inducers antagonize (rifampin); P-gp inhibitors (clopidogrel, amiodarone) increase levels
monitoring for dabigatran
H&H, ECT (ecarine clotting time)
aPTT, CrCl
PG category for dabigatran
PG C
What is the shelf life for dabigatran once opened? Unopened?
30 days once opened
very moisture sensitive
4 months unopened
Drug class for warfarin
coumarin anticoagulants
MoA for warfarin
block Vit K mediated carboxylation of clotting factors VII, IX, X, II & proteins C & S
indications for warfarin
prevention & treatment of venous thrombosis
SE/ADRs for warfarin
easy bruising; skin/tissue necrosis
hypersensitivity rxn
vasculitis
contra-indicaitons for warfarin
active bleeding
prior hx of skin necrosis
Dx-Dx for warfarin
other anticoagulants
gingo biloba
monitoring for warfarin
PT/INR
H&H
drug class for vitamin k
antagonist of coumarin anticoagulants
MoA for vitamin k
promotes liver synthesis of II, VII, IX, X
indications for vitamin k
counteract excess warfarin anticoagulation or vit k deficiency
SE/ADRs for vitamin k
primarily w/ IV dosing-flushing, hypotension, cyanosis, rash
contra-indications for vitamin k
hypersensitivity to vit k (IV)
Dx-Dx for vitamin k
decreases coumarin anticoagulation; Orlistat decreases PO absorption
monitoring for vitamin k
PT/INR
H&H
Drug class for Rivaroxaban
direct factor Xa inhibitor
MoA for Rivaroxaban
directly & selectively inhibits factor Xa
indications for Rivaroxaban
to reduce risk of clots w/ knee & hip replacement, non-valvular atrial fib, DVT/PE
SE/ADRs for rivaroxaban
bleeding, peripheral edema, diarrhea, dizziness
contra-indications for rivaroxaban
active pathological bleeding, hypersensitivity, mod-severe liver disease (Child-Pugh class B or C), coagulopathy
Dx-Dx for rivaroxaban
- CYP3A4/P-gp inhibitors (clarithromycin, flucanazole) increase [drug]
- CYP3A4/P-gp inducers (carbamazepine, phenytoin, rifampin, St Johns wort) decrease [drug]
monitoring for rivaroxaban
- initially CBC, CrCl, LFT
- chronic: none
Pg for rivaroxaban
avoid in PG
drug class for streptokinase
fibrinolytic
MoA for streptokinase
activates conversion of plasminogen to plasmin which degrades fibrin, fibrinogen to lyse cloth (both physiologic & pathologic thrombi)
indications for streptokinase
severe DVT, PE, AMI, occluded AV cannulas
SE/ADRs for streptokinase
bleeding, fever, pruritis
drug class for aminocaproic acid
fibrinolysis inhibitors
MoA for aminocaproic acid
binds to plasminogen & plasma & blocks plasmin lysis of fibrin (but some thrombi continue to form)
indications for aminocaproic acid
state of excess fibrinolysis
SE/ADRs for aminocaproic acid
hypotension, abd discomfort, diarrhea, myopathy, muscle necrosis (rare)
drug class for alteplase
plasminogen activator tPAs
MoA for alteplase
preferentially activates plasminogen bound to fibrin (theory-confines thrombolysis to formed thrombus)
indications for altetplase
thrombus lysis in AMI, PE
SE/ADRs for alteplase
bruising, fever, bleeding, hypotension, reperfusion arrhythmias
drugs class for aspirin
anti-platelet drugs
MoA for aspirin
irreversible inactivation (via acetylation) of cyclo-oxygenase- inhibits synthesis of thromboxane A2-prevents platelet aggregation & vasoconstriction by thromboxane A2
indications for aspirin
secondary prophylaxis s/p MI, CVA
SE/ADRs for aspirin
gastritis (30%), dyspepsia; bleeding, tinnitus (high dose)
contra-indications for aspirin
hypersensitivity, nasal polyposis + bronchospasms
Dx-Dx for aspirin
other anticoagulants, NSAIDs
monitoring for aspirin
none specifically
drug class for clopidogrel
platelet ADP inhibitor
MoA for clopidogrel
irreversibly blocks ADP receptor on platelets preventing platelet/fibrinogen binding & platelet aggregation
indications for clopidogrel
secondary prevention AMI, CVA, PAD
SE/ADRs for clopidogrel
gastritis (27%), abd pain, dyspepsia, thrombocytopenia, leukopenia (rare)
contra-indications for clopidogrel
active bleeding, hypersensitivity
Dx-Dx for clopidogrel
other anti-platelet or anti-coagulatn drugs, gingko biloba (increase effect); atorvostatin, macrolide abs (decrease)
monitoring for clopidogrel
H&H
drug class for abciximab
glycoprotein IIB/IIIA inhibitors
MoA for abciximab
blocks platelet GBIIb/IIIa receptors for thromboxane A2, thrombin, collagen & prevents platelet aggregation
indications for abciximab
coronary artery stent surgery, acute coronary syndrome
SE/ADRs for abciximab
bleeding
contra-indications for abciximab
bleeding
Dx-Dx for abciximab
anticoagulants
How is abciximab administered?
IV
drugs class for dipyridamole
phosphodiesterase inhibitor
MoA for dipyridamole
increases platelet concentration of AMP decreasing platelet aggregation
indications for dipyridamole
post-op primary prophylaxis s/p prosthetic heart valves; prophylaxis after CVA
SE/ADRs dipyridamole
dizziness, HA, abd discomfort, confusion, blurred vision, dyspepsia, hypotension
contra-indications for dipyridamole
hypersensitivity; severe hepatic or renal impairment
Dx-Dx for dipyridamole
aspirin
monitoring for dipyridamole
CrCl, H&H
What is added to dipyridamole to increase effectiveness?
aspirin
drug class for cilostazole
phosphodiesterase inhibitor
MoA for cilostazole
inhibits platelet phosphodiesterase thus preventing aggregation
indications for cilostazole
peripheral artery disease (intermittent claudication)
SE/ADRs for cilostazole
rhinitis, HA, abnormal stools
contra-indications for cilostazole
thrombocytopenia, heart failure, severe renal or hepatic impairment
Dx-Dx for cilostazole
- CYP3A4 inhibitors-macorlide abx (increase effect
- NSAIDs & omeprazole (increase)
- anticoagulants (increase)
monitoring for cliostazole
CrCl, walking distance